# Lafitte Ventures

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lafitte-ventures

- Industry: Healthcare
- Headquarters: Canada
- Website: www.tilray.ca
- Total disclosed funding: $48M
- Latest round: Series A (Feb 7, 2018)
- Investors on record: 2

## About

Lafitte Ventures, Ltd. is a Canadian company focused on the production and distribution of pharmaceutical-grade cannabis products aimed at medical use, catering to patients' diverse health needs.Founded in 2013 in Canada, Lafitte Ventures, Ltd. specializes in medical cannabis products. The company raised USD 153.00 mn in an IPO on July 19, 2018, selling 9 million shares at USD 17 per share. In September 2019, it was acquired by Privateer Holdings, Inc. for an undisclosed amount, completing the transaction in December 2019. The company has engaged in four different deals during its operational history, with its headquarters based in Canada.Tilray Medical offers a comprehensive range of pharmaceutical-grade cannabis products designed to meet the medical needs of patients. Their core product offerings include a variety of cannabis strains, extracts, and formulations tailored for specific medical conditions such as chronic pain, anxiety, and epilepsy. The company focuses on providing high-quality, standardized products that are rigorously tested for safety and efficacy, ensuring that healthcare providers and patients can rely on their effectiveness. Tilray's products are primarily sold in North America and Europe, with a significant emphasis on markets like Canada, Germany, and the United Kingdom. The clientele includes pharmacies, healthcare providers, and patients seeking alternative treatment options, highlighting Tilray’s commitment to improving patient outcomes through innovative medical cannabis solutions.Tilray Medical generates revenue through direct sales of its medical cannabis products to healthcare providers and pharmacies, leveraging a B2B transaction structure. Their business model involves establishing partnerships with healthcare institutions and pharmacies to ensure a steady supply of their products to patients. Transactions typically occur on a per-order basis, with clients placing regular orders based on patient demand and inventory needs. Tilray's flagship products are positioned within various price tiers to accommodate a range of consumer needs, with specific pricing strategies reflecting the quality and therapeutic benefits of their offerings. By fostering strong relationships with their clients, Tilray aims to create a reliable distribution network that supports ongoing revenue growth and market penetration.Looking ahead, Lafitte Ventures, Ltd. plans to expand its product line with new cannabis formulations specifically designed for emerging medical conditions, with launches anticipated in the coming years. The company aims to enter additional international markets, including specific regions in Asia and Europe, by 2025. The recent funding raised in the IPO will be utilized to support product development, enhance distribution capabilities, and facilitate entry into these new geographic areas.

## Funding rounds

- Series A, Feb 7, 2018, $48M — Privateer Holdings, Subversive Capital

## Investors

- Privateer Holdings (https://capitalatlas.ai/funds/privateer-holdings) — Series A
- Subversive Capital (https://capitalatlas.ai/funds/subversive-capital) — Series A